Marker Predicts Outcomes in mCRPC Treated With AR-Targeted Therapy

This video examines the results of a study that looked at the prognostic value of androgen receptor full-length detection using a CTC-based mRNA assay in metastatic castration-resistant prostate cancer patients starting treatment with AR-targeted agents.

In this video, Emmanuel S. Antonarakis, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, discusses the results of a study that examined the prognostic value of full-length androgen receptor (AR-FL) detection using a circulating tumor cell (CTC)-based mRNA assay.

The researchers studied 202 patients with metastatic castration-resistant prostate cancer (mCRPC) starting treatment with the AR-targeted agents abiraterone or enzalutamide. AR-FL status was negative in 97 patients (48%), less than the median in 52 patients (26%), and greater than the median in 53 patients (26%). In Kaplan-Meier analysis clinical outcomes including progression-free and overall survival were significantly different between the three groups.

The study (abstract 132) was presented at the 2017 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, held February 16–18 in Orlando, Florida.